In a new SLAS Technology auto-commentary, two authors of an article recently published in
(Abnormal Scar Identification with Spherical Nucleic Acid Technology) share more insight into this new method. In particular, the authors address point-of-care diagnosis and image acquisition, which are the primary bottlenecks in efficient disease diagnosis.
‘NanoFlare nanotechnology enables biopsy-free diagnosis of skin disease and progression monitoring in response to therapy. This unique method is a minimally-invasive, self-applied alternative that can reduce scarring and infection risks.
Authors David Yeo, Ph.D., and Prof. Chenjie Xu, Ph.D., of the School of Chemical and Biomedical Engineering at Nanyang Technological University (Singapore) use NanoFlare to enable biopsy-free disease diagnosis and progression monitoring in response to therapy.
The method is a minimally-invasive, self-applied alternative that can reduce scarring and infection risks; improve accessibility to disease diagnosis; provide timely feedback of treatment efficacy; and reduce healthcare personnel time and attention, hence the overall healthcare burden.
This vision of simplifying disease diagnosis using topically-applied nanotechnology could change the way skin diseases such as abnormal scars are diagnosed and managed.